46 related articles for article (PubMed ID: 29282712)
21. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas.
Yao L; Schiavi F; Cascon A; Qin Y; Inglada-Pérez L; King EE; Toledo RA; Ercolino T; Rapizzi E; Ricketts CJ; Mori L; Giacchè M; Mendola A; Taschin E; Boaretto F; Loli P; Iacobone M; Rossi GP; Biondi B; Lima-Junior JV; Kater CE; Bex M; Vikkula M; Grossman AB; Gruber SB; Barontini M; Persu A; Castellano M; Toledo SP; Maher ER; Mannelli M; Opocher G; Robledo M; Dahia PL
JAMA; 2010 Dec; 304(23):2611-9. PubMed ID: 21156949
[TBL] [Abstract][Full Text] [Related]
22. Homozygous TMEM127 mutations in 2 patients with bilateral pheochromocytomas.
Eijkelenkamp K; Olderode-Berends MJW; van der Luijt RB; Robledo M; van Dooren M; Feelders RA; de Vries J; Kerstens MN; Links TP; van der Horst-Schrivers ANA
Clin Genet; 2018 May; 93(5):1049-1056. PubMed ID: 29282712
[TBL] [Abstract][Full Text] [Related]
23. A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma.
Buffet A; Venisse A; Nau V; Roncellin I; Boccio V; Le Pottier N; Boussion M; Travers C; Simian C; Burnichon N; Abermil N; Favier J; Jeunemaitre X; Gimenez-Roqueplo AP
Horm Metab Res; 2012 May; 44(5):359-66. PubMed ID: 22517557
[TBL] [Abstract][Full Text] [Related]
24. [Hereditary pheochromocytoma-associated syndromes. Part 1].
Yukina MY; Troshina EA; Beltsevich DG
Ter Arkh; 2015; 87(9):102-105. PubMed ID: 26591561
[TBL] [Abstract][Full Text] [Related]
25. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.
Welander J; Söderkvist P; Gimm O
Endocr Relat Cancer; 2011 Dec; 18(6):R253-76. PubMed ID: 22041710
[TBL] [Abstract][Full Text] [Related]
26. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes.
Gimenez-Roqueplo AP; Dahia PL; Robledo M
Horm Metab Res; 2012 May; 44(5):328-33. PubMed ID: 22328163
[TBL] [Abstract][Full Text] [Related]
27. [Hereditary pheochromocytoma and paraganglioma: screening and follow-up strategies in asymptomatic mutation carriers].
Vermalle M; Tabarin A; Castinetti F
Ann Endocrinol (Paris); 2018 Sep; 79 Suppl 1():S10-S21. PubMed ID: 30213301
[TBL] [Abstract][Full Text] [Related]
28. A Somatic HIF2α Mutation-Induced Multiple and Recurrent Pheochromocytoma/Paraganglioma with Polycythemia: Clinical Study with Literature Review.
Liu Q; Wang Y; Tong D; Liu G; Yuan W; Zhang J; Ye J; Zhang Y; Yuan G; Feng Q; Zhang D; Jiang J
Endocr Pathol; 2017 Mar; 28(1):75-82. PubMed ID: 28116635
[TBL] [Abstract][Full Text] [Related]
29. Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients.
Yamazaki Y; Gao X; Pecori A; Nakamura Y; Tezuka Y; Omata K; Ono Y; Morimoto R; Satoh F; Sasano H
Front Endocrinol (Lausanne); 2020; 11():587769. PubMed ID: 33193100
[TBL] [Abstract][Full Text] [Related]
30. Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma.
Galan SR; Kann PH
Clin Endocrinol (Oxf); 2013 Feb; 78(2):165-75. PubMed ID: 23061808
[TBL] [Abstract][Full Text] [Related]
31. Genetic testing in the clinical care of patients with pheochromocytoma and paraganglioma.
Rana HQ; Rainville IR; Vaidya A
Curr Opin Endocrinol Diabetes Obes; 2014 Jun; 21(3):166-76. PubMed ID: 24739310
[TBL] [Abstract][Full Text] [Related]
32. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era.
Pillai S; Gopalan V; Smith RA; Lam AK
Crit Rev Oncol Hematol; 2016 Apr; 100():190-208. PubMed ID: 26839173
[TBL] [Abstract][Full Text] [Related]
33. Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis.
Lussey-Lepoutre C; Buffet A; Morin A; Goncalves J; Favier J
Cell Tissue Res; 2018 May; 372(2):379-392. PubMed ID: 29427052
[TBL] [Abstract][Full Text] [Related]
34. Rethinking pheochromocytomas and paragangliomas from a genomic perspective.
Castro-Vega LJ; Lepoutre-Lussey C; Gimenez-Roqueplo AP; Favier J
Oncogene; 2016 Mar; 35(9):1080-9. PubMed ID: 26028031
[TBL] [Abstract][Full Text] [Related]
35. Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor.
Elder EE; Elder G; Larsson C
J Surg Oncol; 2005 Mar; 89(3):193-201. PubMed ID: 15719371
[TBL] [Abstract][Full Text] [Related]
36. Genetic testing in pheochromocytoma- and paraganglioma-associated syndromes.
Benn DE; Richardson AL; Marsh DJ; Robinson BG
Ann N Y Acad Sci; 2006 Aug; 1073():104-11. PubMed ID: 17102077
[TBL] [Abstract][Full Text] [Related]
37. Review of sequencing platforms and their applications in phaeochromocytoma and paragangliomas.
Pillai S; Gopalan V; Lam AK
Crit Rev Oncol Hematol; 2017 Aug; 116():58-67. PubMed ID: 28693800
[TBL] [Abstract][Full Text] [Related]
38. Novel hereditary forms of pheochromocytomas and paragangliomas.
Dahia PL
Front Horm Res; 2013; 41():79-91. PubMed ID: 23652672
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas.
Amorim-Pires D; Peixoto J; Lima J
Cytogenet Genome Res; 2016; 150(3-4):227-241. PubMed ID: 28231563
[TBL] [Abstract][Full Text] [Related]
40. Hereditary pheochromocytoma and paraganglioma.
Mazzaglia PJ
J Surg Oncol; 2012 Oct; 106(5):580-5. PubMed ID: 22648936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
